Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung

Luisella Righi, Marco Volante, Ida Rapa, Veronica Tavaglione, Frediano Inzani, Giuseppe Pelosi, Mauro Papotti

Research output: Contribution to journalArticlepeer-review

Abstract

Among alternative therapeutic strategies in clinically aggressive neuroendocrine tumors (NETs) of the lung, promising results have been obtained in experimental clinical trials with mammalian target of rapamycin (mTOR) inhibitors, though in the absence of a proven mTOR signaling activation status. This study analyzed the expression of phosphorylated mTOR (p-mTOR) and its major targets, the ribosomal p70S6-kinase (S6K) and the eukaryotic initiation factor 4E-binding protein 1 (4EBP1) in a large series of 218 surgically resected, malignant lung NETs, including 24 metastasizing typical carcinoids, 73 atypical carcinoids, 60 large cell neuroendocrine carcinomas (LCNECs), and 61 small cell carcinomas (SCLCs). By immunohistochemistry, low-to-intermediate-grade tumors as compared with high-grade tumors showed higher levels of p-mTOR and phosphorylated S6K (p-S6K) (P

Original languageEnglish
Pages (from-to)977-987
Number of pages11
JournalEndocrine-Related Cancer
Volume17
Issue number4
DOIs
Publication statusPublished - Dec 2010

ASJC Scopus subject areas

  • Endocrinology
  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung'. Together they form a unique fingerprint.

Cite this